Drug Development
IN-HOUSE RD PROJECTS
Bio-Betters Drugs are new drugs designed from existing ones with improved properties such as higher efficacy, selectivity, stability, half-life, and/or lower toxicity/immunogenicity. The projects are subject to adjustment according to validation outcomes and market competitiveness.
Projects
Super Agonist Antibody Platform
AgTa-101
(Bio-Better)
AgTa-106
(Bio-Better)
AgTa-234
(Bio-Better)
AgTa-203
(Bio-Better)
Diseases
(Platform)
Immune Diseases
Cardiovascular Diseases
Tumors
Liver Tumor
Current Status
Validating with AI and in vitro testing.
Optimizing the candidates with AI and validating in wet-lab.
Optimizing the candidates with AI and validating in wet-lab.
Optimizing the candidates with AI and validating in wet-lab.
Optimizing the candidates with AI and validating in wet-lab.
Projects
AgTa-279 (Bio-Better)
AgTa-101 (Bio-Better)
AgTa-124 (Cyclic Peptide)
AgTa-274 (Cyclic Peptide)
AgTa-301 (Cyclic Peptide)
AgTa-482 (Cyclic Peptide)
Diseases
Rheumatoid Arthritis
IBD (UC & Crohn's)
Asthma & Atopic Dermatitis
Cancers
Fibrosis
Diabetes & Fatty Organs
Current Status
Selecting the best candidates with Al and testing in vitro/vivo disease models
Selecting the best candidates with AI and testing in vitro/vivo disease models
Selecting the best candidates with AI and testing in vitro/vivo disease models
Selecting the best candidates with AI and testing in vitro/vivo disease models
Screening the best candidates with AI and testing in vitro/vivo disease models
Screening the best candidates with AI and testing in vitro/vivo disease models
Estimated Completion Date
Q1 2026
Q2 2026
Q3 2026
Q3/Q4 2026
Q3/Q4 2026
Q1 2027
